Free Newsletter
Report: GSK to beat Pfizer by 2012
Free newsletter via e-mail
Tools
Who's No. 1 in Big Pharma? Well, in a few years it won't be Pfizer, according to a new industry report. URCH Publishing predicts that GlaxoSmithKline will overtake Pfizer as the world's largest by 2012. Pfizer won't even be able to hang onto second place, the report says; that will belong to Roche.
Currently, it's Pfizer in the lead with a market share of 6.2 percent. GSK comes in second with 5.4 percent, and Roche boasts a third-place 4.3 percent. That's all going to change, though, as only two of today's top 10 are expected to post industry-beating growth: Roche and Novartis. The global pharma market is poised for compound annual growth of 5.5 percent over the next four years, to $929 billion, the report states. Roche is expected to rack up 6.2 percent and Novartis 6.1 percent.
What about other big-name drugmakers? Johnson & Johnson and Merck are expected to generate only "stagnant growth" through 2012, URCH predicts.
The report's reasoning behind its sales projections is familiar: Future growth will be limited by increased generic competition, a lack of new blockbusters and high prescription co-pays for insured consumers.
- see the release from URCH Publishing
Related Articles:
The Top 15 R&D Budgets
GlaxoSmithKline does better in Q3
Witty: Diversifying and derisking GSK
Pfizer plans big push into generics
Is Pfizer's pipeline a pipedream?
Pfizer's future rests with biotech (Sept 2007)
Comments
By Mukul | Posted 10:44am | November 9, 2008
This report coming in the midst of the Global financial turmoil is indeed interesting. It reveals a clear tilt towards European acendabcy in the Healthcare market ,as all the firms - GSK,Roche & Novartis - expected to dominate the Global market in the next few Years would be of European origion. However the lifeline for Big Pharma continues to be Biotech - and US still remains the Hub of innovation.
By Anonymous | Posted 12:55am | November 20, 2008
US is still the Hub of innovation but for how long? Scientists continue to be layoff right from left...and many Biotech companies are closing down b/c under this economic times, they can't sustain themselves...then, if BigPharma's scientists are removed and Biotech's lifeline is threatened...Where is innovation coming from? What type of innovation is BigPharma going to rely on?
Where is the quality gone!
All that will show up in BigPharma's pipeline...go figure that out...What has happened to the innovation model?
By Anonymous | Posted 10:48pm | January 20, 2009
Why cant the beomoths Pfizer and the other bigpharm companies band together to fight big insurance who forces their clients to buy generics by raising deductables for name brand.Look many of my patients would buy name brand direct from the pharmacy company if their prices became more competative. People know that generic products can be a real joke and not work well compared to name brand. So get moving and do an advertising campaign against insurance companies saving huge amounts on your premiums by giving away junk generics for practically nothing. Afterall you only get what you pay for and people know that about other consumer products. Wouldn't you think meds would be a hi priority on their list.
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact
